Filing Summary
Business Context and Reporting Period
Pliant Therapeutics, Inc. filed a Form 8-K dated November 16, 2022, under Item 5.02. The filing reports a board resignation and related governance changes; it does not provide quarterly or annual financial results.
Key Financial Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material Changes
- Neil Exter, an independent director who had served on the Board since 2015, retired from the Board and as a member of its Compensation Committee effective November 16, 2022.
- The company stated that Mr. Exter’s retirement was not due to any disagreement with the company regarding its operations, policies, or practices.
- The Board approved reducing its size from nine to eight members, effective November 17, 2022.
Outlook, Risks, and Unusual Items
The filing does not disclose updated guidance, management outlook, contingencies, or operational risks. The principal disclosed item is the director retirement and corresponding reduction in Board size.
Investor Verification Items
- Verify the effective dates of Mr. Exter’s Board and Compensation Committee retirement.
- Confirm the Board’s revised size of eight members and any subsequent director appointments or committee changes.
- Review later filings for any governance, compensation, or strategic effects associated with the Board change.